RadNet, Inc. Q1 2026 Earnings Recap

RadNet's stock declined 3.9% post-earnings as investors responded to surprisingly cautious outlook commentary and deceleration signals within the Digital Health segment, despite reported revenue and EBITDA gains. The market appears concerned that margin expansion and growth momentum may not sustain at the current pace.

Key Takeaways

• Revenue and adjusted EBITDA both set first quarter records, up 22.1% and 36.3% year-over-year, respectively, though results were impacted negatively by $13 million in revenue and $9 million in EBITDA from severe weather in Jan-Feb.
• Adjusted EBITDA margin improved by 115 basis points year-over-year, or 52 basis points on a weather-adjusted basis, driven by a shift toward higher-margin advanced imaging protocols now representing 29.3% of procedural volume.
• PET/CT procedures increased 35.2% aggregate and 14.7% same-center, primarily fueled by clinical demand in prostate cancer staging and neurological applications.
• RadNet completed multiple acquisitions including Radiology Regional (13 centers) and Northwest Radiology (6 centers), with ongoing integration efforts focusing on AI-powered operational enhancements.
• Despite strong operational commentary, cautious future guidance and possible Digital Health segment deceleration weighed on sentiment, reflecting concern about sustaining margin and growth trajectory amid integration and investment costs.